PURPLE BIOTECH LTD-ADR (PPBT)
US74638P1093 - ADR
The trading volume of these stocks is deviating from the norm in today's session.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Let's have a look at the gap up and gap down stocks in today's session.
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company...
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Purple Biotech Reports Third Quarter 2024 Financial Results
Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024...
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when...
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the...
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal...
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival...
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (
PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024
PPBT stock results show that Purple Biotech beat analyst estimates for earnings per share the second quarter of 2024.
PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Purple Biotech (NASDAQ:PPBT) just reported results for the second quarter of 20...
Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights
Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting...
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
REHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company...
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company...
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the...
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with...